Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.57, No.1, p.8-14, 2010 |
||
Title: Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma | ||
Author: J. MINARIK, V. SCUDLA, J. BACOVSKY, M. ZEMANOVA, T. PIKA, M. ORDELTOVA, K. LANGOVA | ||
Abstract: We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI ven after 40 months (median overall survival 25 vs 10months, p = 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients. |
||
Keywords: myeloma – prognostication – proliferative index – biological therapy | ||
Year: 2010, Volume: 57, Issue: 1 | Page From: 8, Page To: 14 | |
doi:10.4149/neo_2010_01_008 |
||
|
download file |
|